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Vaccines  induce  protective  immunity  against 
numerous infectious diseases. However, cur-
rent vaccines have limited efficacy against chal-
lenging infections like tuberculosis, malaria, and 
HIV, where Th1-type T cell immunity likely has 
a potentially important role (Seder and Mascola,   
2003). Proteins represent a potential route to 
safe new generation vaccines (Ulmer et al., 
2006), but, typically, these are poorly immuno-
genic for T cells when administered alone. 
Therefore, special attention is being given to 
additional adjuvants or enhancers of immunity. 
Adjuvants activate innate immunity and, in par-
ticular, the maturation of antigen-presenting 
immunostimulatory DCs (Pulendran and Ahmed, 
2006; Kool et al., 2008). To understand adju-
vant action, and to identify optimal ones, it is 
necessary to move beyond the current focus on 
in vitro assays and selected monoclonal or TCR 
transgenic T cells to the intact animal and pa-
tient. This avenue of research should also help 
to identify mechanisms that link innate responses 
to adaptive immunity in vivo.
Adjuvants can stimulate innate immunity 
by interacting with specialized pattern recogni-
tion receptors (PRRs), including Toll-like re-
ceptors (TLRs; Akira et al., 2006; Kawai and 
Akira, 2009) and nucleotide-binding oligo-
merization domain receptors (Li et al., 2008). 
DCs express a repertoire of PRR, allowing the 
recognition of a range of pathogen constitu-
ents. The engagement of PRR on DCs leads to 
de novo transcription and secretion of cyto-
kines and chemokines, enhanced antigen pre-
sentation capacity, and migration to lymphoid 
tissues where the DCs interact with T cells and 
B cells to initiate and shape the adaptive im-
mune response. The type of stimulus condi-
tions DCs to adopt a Th1- or Th2-polarizing 
function (Mazzoni and Segal, 2004; Kwissa et al., 
2007). However, many cell types, including 
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Relative to several other toll-like receptor (TLR) agonists, we found polyinosinic:polycyti-
dylic acid (poly IC) to be the most effective adjuvant for Th1 CD4+ T cell responses to a 
dendritic cell (DC)–targeted HIV gag protein vaccine in mice. To identify mechanisms for 
adjuvant action in the intact animal and the polyclonal T cell repertoire, we found poly IC 
to be the most effective inducer of type I interferon (IFN), which was produced by  
DEC-205+ DCs, monocytes, and stromal cells. Antibody blocking or deletion of type I IFN  
receptor showed that IFN was essential for DC maturation and development of CD4+  
immunity. The IFN-AR receptor was directly required for DCs to respond to poly IC. STAT 1  
was also essential, in keeping with the type I IFN requirement, but not type II IFN or IL-12 
p40. Induction of type I IFN was mda5 dependent, but DCs additionally used TLR3. In bone 
marrow chimeras, radioresistant and, likely, nonhematopoietic cells were the main source  
of IFN, but mda5 was required in both marrow–derived and radioresistant host cells for  
adaptive responses. Therefore, the adjuvant action of poly IC requires a widespread innate  
type I IFN response that directly links antigen presentation by DCs to adaptive immunity.
© 2009 Longhi et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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helicase MDA5, resulting in activation of IRF-3 and represent-
ing a major pathway for the production of type I IFNs in a 
TLR-independent fashion (Kato et al., 2006). Poly IC is a 
strong inducer of type I IFN. Although DCs and macrophages 
produce type I IFN upon poly IC stimulation in vitro, many 
nonhematopoietic cell types potentially could provide a source 
of this cytokine in vivo (Alexopoulou et al., 2001; Gitlin et al., 
2006). In addition, the critical question of whether type I IFN 
is required for the adjuvant effect of poly IC and its mechanism 
of action in situ has not been addressed.
In this paper, we study the mechanism whereby poly IC 
adjuvants CD4+ Th1 immunity for an HIV gag protein vaccine 
that is targeted in vivo to DCs within a monoclonal antibody 
to the uptake receptor DEC-205/CD205 (Trumpfheller   
et al., 2008). We found that poly IC is a superior adjuvant 
and then we made several findings on its effects in vivo. First, 
type I IFN is the dominant driver of two innate cellular   
responses: the maturation of DCs and the activation of NK 
cells to produce type II IFN. Second, type I IFN must act 
directly on DCs to induce their maturation into immuno-
stimulatory cells and also is necessary for the generation of   
a Th1 CD4+ adaptive T cell response, whereas IL-12 and 
type II IFN-R are not. Third, both bone marrow–derived 
and stromal cells play essential roles in providing type I IFN. 
These data illustrate that poly IC adjuvants Th1 CD4+ T cell 
immunity by replicating the early systemic effects of viral   
infection through its superior and widespread induction of 
type I IFN.
RESULTS
Poly IC is a superior adjuvant for CD4+ T cell responses  
to a protein vaccine
We had previously shown that poly IC was a superior adju-
vant to monophosphoryl lipid A for inducing strong protec-
tive CD4+ T cell responses to HIV gag p24 delivered within 
an anti-DEC antibody (Trumpfheller et al., 2008). To find the 
most appropriate adjuvant for this new approach to protein-
based vaccines, we extended our analysis to other TLR ligands, 
including MALP-2 (TLR2/TLR6), Pam3Cys (TLR1/TLR2), 
poly IC (TLR3), poly ICLC (TLR3-complexed poly IC with 
carboxymethylcellulose and poly-l-lysine to improve resis-
tance to ribonucleases), LPS (TLR4), R-848 (TLR7/TLR8) 
delivered as an aqueous compound or within a topical cream, 
and CpG (TLR9). Mice were immunized with -DEC-gag 
p24 mAb and specific adjuvants twice i.p. over 4 wk. 1 wk   
after the final injection, antigen-specific responses were evalu-
ated by IFN- secretion in response to gag p24 peptides, 
primarily by multicolor flow cytometry.
Poly IC, together with its analogue poly ICLC, induced 
stronger gag-specific CD4+ T cell responses compared with 
the other adjuvants (Fig. 1, A and B) with frequencies of >1% 
of IFN- producing CD3+CD4+ T cells after i.p. injection. 
The improved CD4+ T cell responses with poly IC and poly 
ICLC were also evident at the single cell level when IL-2 and 
TNF- were measured (Fig. S1). ELISA assays showed that   
IL-4 and IL-17 were not induced during the adjuvant role of 
nonhematopoietic cells, express PRR and produce cytokines 
during innate immunity (Nolte et al., 2007). To understand 
adjuvant action, it will likely be necessary to understand the 
contribution of cytokines and different cellular sources of   
cytokines to the initiation of immunity from the naive poly-
clonal repertoire.
Among innate inflammatory cytokines, type I IFNs are 
considered to be major players for linking innate to adaptive 
immunity. First uncovered for their innate antiviral activity 
(Nagano and Kojima, 1954; Lindenmann et al., 1957), type I 
IFNs also enhance adaptive responses. They activate DCs, criti-
cal antigen-presenting cells for initiating immunity (Blanco   
et al., 2001), by promoting the expression of costimulatory 
molecules (Luft et al., 1998; Gallucci et al., 1999; Ito et al., 
2001). This includes human blood monocytes, where type I 
IFN can stimulate differentiation into DCs (Paquette et al., 
1998; Santini et al., 2000). Type I IFN–treated DCs prime T 
cells in vitro more effectively. The DCs also up-regulate ex-
pression of lymph node–homing CCR7 and exhibit stronger 
migratory capacity compared with DCs differentiated with 
other cytokines (Paquette et al., 1998; Parlato et al., 2001). 
Type I IFN further promotes cross-priming of CD8+ T cells 
by direct stimulation of DCs (Le Bon et al., 2003). Le Bon   
et al. (2001) showed that type I IFNs act on ex vivo–derived 
DCs to become better stimulators of antibody immunity. 
Nevertheless, the effects of type I IFN on DCs in situ need 
definition to understand the link between the innate produc-
tion of cytokines to adaptive immunity.
Type I IFNs also have direct effects on T cells, particu-
larly CD8+ T cells (Tough et al., 1996), by extending their 
survival during antigen-driven clonal expansion (Kolumam 
et al., 2005; Le Bon et al., 2006). In contrast, the importance 
of type I IFNs in the generation of antigen-specific CD4+  
T cell responses is uncertain. Type I IFN inhibits secretion of 
Th2 cytokines (IL-4 and IL-5) and stimulates type II IFN or 
IFN- production (Brinkmann et al., 1993; Wenner et al., 
1996). Type I IFNs inhibit the death of activated CD4+  
T cells (Marrack et al., 1999), a finding which was later 
extended to the adoptive transfer of antigen-specific CD4+  
T cells lacking the expression of type I IFN receptors (Havenar-
Daughton et al., 2006). However, although it was originally 
believed to induce STAT4 activation, type I IFN failed   
to promote Th1 commitment in human and mouse CD4+  
T cells in vitro. Despite induction of detectable STAT4 tyro-
sine phosphorylation, the activation was transient and insuffi-
cient to drive Th1 development in the absence of IL-12 
(Berenson et al., 2004; Ramos et al., 2007). Therefore, the 
effect of type I IFNs on the generation of antigen-specific 
CD4+ T cells in vivo is unclear from these observations.
Several TLR agonists are currently being evaluated as adju-
vants for vaccine development. Among them, synthetic dou-
ble-stranded RNA, polyinosinic:polycytidylic acid (poly IC), 
induces inflammation and long-lasting T cell immunity (Salem 
et al., 2006; Trumpfheller et al., 2008; Stahl-Hennig et al., 
2009). Poly IC is recognized by TLR3 located mostly in endo-
somal membranes. Also, poly IC binds the cytoplasmic RNA JEM VOL. 206, July 6, 2009 
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weak (Fig. 1, A and B). To verify the activity of the adjuvants, 
we also measured antibody responses to HIV gag and found 
that all the adjuvants were active, with LPS being at least as 
poly IC or poly ICLC, verifying a polarized Th1 response   
(Fig. 1 C). The second most active adjuvant was R-848 ap-
plied in a cream to the skin, but the other adjuvants were 
Figure 1.  Poly IC is a superior adjuvant to elicit CD4+ T cell immunity. (A) CxB6 F1 mice were primed and boosted 4 wk apart with 5 µg -DEC-p24 
and 50 µg poly IC, 50 µg Pam3cys, 0.5 µg Malp2, 50 µg poly ICLC, 10 µg LPS, 50 µg CpG, or R-848 cream. R-848 cream was applied topically over 5 cm2 
on the back of shaved mice. IFN- secretion in gated CD3+CD4+ splenic T cells in response to HIV gag p24 peptides was measured 1 wk after boost. (B) As 
in A, but means ± SD from five (poly IC), three (poly ICLC, R-848, and CpG), and two (Malp-2, Pam3cys, and LPS) experiments, with three mice per group. 
(C) CxB6 F1 mice were primed and boosted 4 wk apart with 5 µg -DEC-p24 and 50 µg poly IC. 1 wk after boost, bulk splenocytes were stimulated with 
gag p24 peptide mix or control peptide mix for 3 d. The concentrations of the indicated cytokines and chemokines were measured in cell culture superna-
tants by luminex. Samples were acquired in duplicate and analyzed by ELISA. Bars represent the mean ± SD from two experiments (six mice total).  
(D) Mice were immunized as in A. 1 wk after boost, gag-specific antibodies in serum samples were measured by ELISA. Data are given as OD mean ± SD 
from two independent experiments (five mice total).1592 ROLE OF TYPE I INTERFERON IN POLY IC ADJUVANTICITY | Longhi et al.
blocked by simultaneous injection of IFNAR1 (anti–IFN- 
receptor) antibody or isotype control. After 12 h, expression   
of MHC-II and costimulatory molecules (CD40 and CD86) 
on DEC+ and DEC DCs was analyzed by flow cytometry 
(Fig. 3 A). Blocking type I IFN receptor effectively reduced 
DC maturation, as monitored by the up-regulation of these 
immunostimulatory molecules in response to poly IC.
To directly evaluate the stimulatory capacity of DCs after 
poly IC stimulation with or without blockade of type I IFN 
receptors, we isolated the CD11c+ DC fraction from the 
spleen, fixed the cells with formaldehyde to block further 
differentiation in culture, and added the DCs in graded doses 
to allogeneic T cells in an MLR. DCs from poly IC–treated 
mice  became  active  stimulators  of  the  allogeneic  MLR, 
whereas blockade of type I IFNs abrogated this effect (Fig. 3 B), 
showing that this cytokine was essential for DC maturation in 
response to the poly IC adjuvant.
Direct IFNAR signaling is critical for DC activation in vivo
To determine if type I IFN had to act directly on DCs to 
bring about maturation, we made mixed bone marrow chi-
meras in which the injected bone marrow suspension was a 
50:50  mixture  of  CD45.1  WT  and  CD45.2  IFN-AR/ 
cells (Fig. 4 A). When poly IC was given to these chimeric 
mice, only the CD45.1 WT cells were able to up-regulate 
costimulatory molecules and MHC class II (Fig. 4 B) and ex-
hibit enhanced MLR stimulatory activity (Fig. 4 C and Fig. S3). 
Therefore, Type I IFN directly promotes maturation of DCs 
to link innate to adaptive immunity.
active as poly IC (Fig. 1 D). These results encouraged us to 
compare the innate response to poly IC relative to other ago-
nists to help explain its superior adjuvant role in inducing 
Th1 type CD4+ T cell immunity.
The innate response to poly IC uniquely leads to high levels 
of serum type I IFN
To assess the innate response to poly IC and poly ICLC, we 
studied the systemic release of inflammatory cytokines, a proto-
type response to agonists for PRR. We did ELISA assays on se-
rum at 1, 3, 6, or 20 h after administration of different TLR 
ligands i.p., measuring IL-6, TNF-, IL-12p40, IFN-, IFN-, 
and IFN-. All TLR agonists, to different extents, induced pro-
duction of IL-6, TNF-, and IL-12 p40 (Fig. 2), whereas serum 
IL-12p70, IL-1, and IL-10 were not detected (not depicted). 
Interestingly, production of type I and type II IFNs was more re-
stricted, being detected primarily with poly IC, poly ICLC, and 
R-848. Detection of IFN- and IFN- was transient, peaking   
at 3–6 h, and was highest with both poly IC and poly ICLC   
(Fig. 2). Thus, strong type I IFN production is a special feature of 
poly IC, suggesting a role for IFN in its adjuvant effect.
Poly IC induces activation of DCs
Poly IC matures both mouse and human DCs (Verdijk et al., 
1999; Blanco et al., 2001; Lopez et al., 2004; Tsujimoto, 2006), 
and  this  maturation  was  shown  to  depend  on  type  I  IFN 
(Honda et al., 2003). However, these experiments were per-
formed in vitro. To assess DC maturation in vivo, mice were 
injected with 50 µg poly IC, and the effect of type I IFN was 
Figure 2.  Induction of inflammatory cytokines in the serum by TLR ligands. Mice were treated i.p. with 50 µg poly IC, 50 µg Pam3cys, 0.5 µg 
Malp2, 10 µg LPS, 50 µg poly ICLC, 50 µg CpG, and 5 cm2 of 0.2% R-848 cream. IL-6, TNF-, IL-12p40, IFN-, IFN-, and IFN- were analyzed in serum at 
different time points (means of four mice). Error bars indicate the mean ± SD. Data are representative of two similar independent experiments.JEM VOL. 206, July 6, 2009 
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(Walzer et al., 2005). In concordance with previous studies, 
poly IC failed to directly activate mouse NK cells (Fig. 5 C). 
We then considered that NK activation was indirect and a   
result of stimulation by type I IFNs. To test this, mice were   
injected with poly IC 1 h after injection of anti-IFNAR1 or 
isotype control. Antibody treatment dramatically reduced 
IFN- production by NK cells (Fig. 5 D). Collectively, these 
results highlight the importance of type I IFN during the in-
nate responses of both DCs and NK cells in the intact animal.
Poly IC directly activates multiple cell types to produce  
type I IFN
Type I IFNs are rapidly produced by many cell types in re-
sponse to immune and/or inflammatory stimuli. Poly IC was 
previously shown to stimulate mouse conventional DCs (cDCs), 
bone morrow–derived DCs, and macrophages to produce 
Poly IC induces IFN- production by NK cells
An additional component to the innate response to the in vivo 
administration of poly IC is the rapid activation of NK cells to 
produce IFN- (Salem et al., 2006). Because we had observed 
an innate IFN- response to poly IC, we assessed NK cells as 
a possible source. We found that CD11cintDX5+ NK cells 
were major producers of IFN-, whereas other cells, includ-
ing CD11chighDX5 DCs were inactive (Fig. 5, A and B).
Human NK cells respond directly to poly IC and CpG to 
produce IFN- (Lauzon et al., 2006) but, in contrast, purified 
mouse NK cells fail to respond directly to TLR agonists and 
require the presence of DCs or IL-12 (Sawaki et al., 2007). To 
assess the latter possibility, highly purified splenic NK cells 
were incubated overnight in the presence of poly IC, and 
IFN- production was measured by ELISA. As a positive con-
trol, the NK cells were stimulated with rIL-12 and rIL-15 
Figure 3.  Type I IFN signaling controls DC maturation. (A) 1 h after 100 µg of anti-IFAR1 blocking antibody or isotype control, mice were stimulated 
with 50 µg poly IC for 12 h and analyzed for cell surface MHC-II, CD86, and CD40 on DEC+ and DEC DCs. (B) As in A, but graded numbers of fixed splenic 
DCs from BALB/C mice were added for 5 d to 2 × 105 allogeneic C57BL/6 T cells. T cell proliferation was detected by CFSE dilution of CD3+ cells. Data are 
representative of three experiments.1594 ROLE OF TYPE I INTERFERON IN POLY IC ADJUVANTICITY | Longhi et al.
Although production of type I IFN by pDCs requires acti-
vation of the TLR system, cDCs and fibroblasts were shown 
to secrete type I IFNs in response to viral infection in a cyto-
solic helicase-dependent fashion (Kato et al., 2005). Because 
poly IC can be recognized by the RNA helicase mda5, we 
next tested if poly IC–induced IFN- required this PRR. 
Monocytes, DEC+ DC, and stromal cells from WT, mda5/, 
or TLR3/ mice were stimulated in vitro with poly IC as de-
scribed in the previous paragraph. Interestingly, the production 
of IFN- by all cell types was comparable between WT and 
TLR3/ cells, whereas it was severely impaired in mda5/ 
cells (Fig. 6 C). Similar results were obtained when we mea-
sured the release of type I IFN into the serum of mice geneti-
cally deficient in these PRRs after poly IC injection (Fig. S2), 
confirming prior observations (Gitlin et al., 2006). DEC+ DCs 
were also able to produce small amounts of IFN- in an mda5-
independent fashion (Fig. 6 C), but this was ablated in mice 
doubly deficient in TLR3 and mda5 (not depicted).
To investigate the extent to which type I IFN in vivo re-
quired hematopoietic cells, e.g., DEC+ DCs and monocytes, 
and nonhematopoietic cells, e.g., endothelia, stromal bone 
marrow chimeras were generated by reconstituting mda5/ 
mice with WT bone marrow or, alternatively, WT mice 
type I IFN (Gitlin et al., 2006; Kumagai et al., 2007). Splenic 
cells were sorted into several different cell types, stimulated in 
vitro with poly IC, and tested for the production of type I IFN. 
First, spleen cells were preenriched by magnetic depletion   
of B, T, and erythroid cells with antibodies to CD19, CD3, and 
TER119. The depleted cells were then sorted based on the 
expression of a set of specific markers. NK cells were CD3DX5+, 
plasmacytoid DCs (pDCs) were CD11cintDX5B220+, and 
cDCs were CD11chiDX5CD8 or CD8+DEC-205+ (Fig. 6 A;   
Asselin-Paturel et al., 2005; Blasius et al., 2007; Dudziak   
et al., 2007). To sort granulocytes and monocytes, we gated for 
CD11bhi cells and then isolated LyC6hi granulocytes and CD115+ 
monocytes.  Macrophages  were  defined  as  CD11blowF4/80+ 
cells (Fig. 6 A; Taylor et al., 2005; Randolph et al., 2008).
When each of the sorted cell subsets (3 × 105 cells/well) 
were stimulated overnight with poly IC, both CD8+DEC+ 
DCs and monocytes produced type I IFN, whereas CD8 
DCs, pDCs, NK, granulocytes, and macrophages did not 
(Fig. 6 B). To test the capacity of nonhematopoietic cells to 
produce IFN-, we used splenic stromal cells (105 cells/well) 
that had been expanded from CD45-negative spleen cells. 
Similar to monocytes and DEC+ DCs, stromal cells were able 
to produce type I IFN (Fig. 6 B).
Figure 4.  Direct type I IFN signaling of DCs is required for their maturation. Mixed bone marrow chimeras were prepared with a 50:50 mixture of 
bone marrow from WT (CD45.2) and IFNAR/ (CD45.2+) mice. (A) Gating strategy for WT (CD45.2) and IFNAR/ (CD45.2+) DCs 4–6 wk after chime-
rism. (B) The chimeras were stimulated with 50 µg poly IC or PBS for 12 h. Expression of CD86, MHC-II, and CD40 on WT and IFNAR/ DCs, was analyzed 
by FACS. Arrows show increased up-regulation of costimulatory molecules in IFNAR/ DCs. (C) The chimeras were stimulated as in B. After CD11c enrich-
ment, WT and IFNAR/ CD11chi were FACS sorted as in A. Graded numbers of fixed B6.WT or B6.IFNAR/ splenic DCs were added for 5 d to 2 × 105  
allogeneic Balb/C T cells. T cell proliferation was detected by CFSE dilution of CD3+ cells. Cells numbers are indicated as 103. Data are representative of  
two similar independent experiments.JEM VOL. 206, July 6, 2009 
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Type  I  IFNs  may  regulate  Th1  responses  by  indirect 
mechanisms. IFN- signaling can up-regulate IFN- pro-
duction by DCs, promoting the ability of naive T cells to re-
spond to IL-12 (Wenner et al., 1996; Montoya et al., 2002), 
whereas type I IFN can up-regulate expression of IL-12R2 
on human CD4+ T cells, increasing responsiveness to IL-12, 
a pivotal cytokine for Th1 responses (Rogge et al., 1997). To 
determine if type I IFN might additionally require either in-
creased IFN- or IL-12 signaling, CD4+ T cell responses to 
DEC-p24 and poly IC were analyzed in IFN-R (IFN- re-
ceptor) and IL-12 p40–deficient mice. Both IFN-R/ and 
IL-12p40/ mice mounted similar responses to WT mice 
(Fig. 7, D and E and Fig. S4, C and D), implying that type I 
IFN, but not type II IFN or IL-12, was directly required for 
poly IC to induce polarized Th1 immunity.
IFN from both bone marrow–derived and nonhematopoietic 
cells is needed for the adjuvant function of poly IC
Because mda5 and TLR3 are the major PRRs for type I IFN 
production  in  response  to  poly  IC,  and  both  receptors   
were needed to induce gag-specific CD4+ T cell responses 
(Trumpfheller et al., 2008), we analyzed chimeric mice in which 
either the bone marrow donor or recipient were lacking both 
mda5 and TLR3. The B and T cells in these mice were >98% 
donor in origin after typing with anti-CD45.1 and anti-
CD45.2 (unpublished data). In each case, i.e., when either 
the hematopoietic cells or nonhematopoietic cells could not 
were reconstituted with mda5/ marrow. The different chi-
meras were injected i.p with poly IC, and serum was col-
lected after 6 h. Interestingly, WT recipients of mda5/ 
marrow produced high levels of IFN-/, whereas mda5/ 
recipients  of  WT  marrow  were  severely  compromised   
(Fig. 6 D). These data demonstrated that stimulation of radiore-
sistant cells, but not bone marrow–derived cells, was required for 
the bulk of type I IFN production after poly IC treatment.
Production of type I IFNs by poly IC, but not IL-12 p40,  
is needed for Th1 immunity
To determine if type I IFN could influence the development of 
adaptive Th1 immunity, we first analyzed gag-specific CD4+ T 
cells responses after IFNAR1 blocking of mice immunized with 
either -DEC-p24 or nontargeted gag p41 protein. In both 
cases, the adjuvant effect of poly IC was markedly reduced by 
IFNAR1 blocking compared with isotype control (Fig. 7 A and 
Fig. S4 A). TNF- and IL-2 production likewise was also   
severely reduced (unpublished data). Similar results were ob-
tained with IFNAR/ mice, which were unable to develop 
adaptive Th1 immunity in response to -DEC-p24 plus poly 
IC (Fig. 7 B). To extend the evidence for a critical role of type 
I IFNs, we studied mice with a genetic deletion of STAT1, the 
major signal transducer for type I IFNs. As anticipated, immuni-
zation with either -DEC-p24 or p41 protein was totally ablated 
in STAT1/ mice (Fig. 7 C and Fig. S4 B). Thus, the stimula-
tion of type I IFNs by poly IC is required for its adjuvant role.
Figure 5.  NK cells are major producers of IFN- after poly IC. Mice were injected i.p. with 50 µg poly-IC or PBS. After 2 h, spleens were collected and a 
single cell suspension of splenocytes was incubated with 10 µg/ml BFA for 3 h before intracellular staining for IFN-. (A) Five color flow cytometry to identify 
IFN-–positive splenocytes. (B) As in A, but production of IFN- by NK cells gated as CD3 DX5+ cells. Means ± SD of four experiments. (C) Highly purified 
CD3 DX5+ NK cells. 3 × 105 cells/well were stimulated with 50 µg/ml poly IC or, as a positive control, a combination of rIL-12 and rIL-15. After 12 h, IFN- in 
culture supernatants was detected by ELISA. Means ± SD of three independent experiments are shown. (D) Mice were injected with poly IC and anti-IFAR1 
blocking antibody or isotype control. Production of IFN- was detected by intracellular staining. Mean ± SD from three experiments is shown.1596 ROLE OF TYPE I INTERFERON IN POLY IC ADJUVANTICITY | Longhi et al.
animal and a polyclonal T cell repertoire. In this paper, we have 
analyzed the adjuvant mechanism of poly IC in an experimental 
system in which HIV gag is the antigen and the elicited immune 
response is durable, broad (many peptides recognized), and capa-
ble of providing protective immunity (Trumpfheller et al., 2008). 
In contrast to the findings in the current paper, many prior studies 
of adjuvants, like CpG and LPS, have analyzed isolated cells and 
the clonal expansion of TCR transgenic T cells (Lore et al., 2003; 
Napolitani et al., 2005; Thompson et al., 2005; He et al., 2007; 
Mata-Haro et al., 2007).
Our interest in poly IC was initially based on two sets of 
findings. Poly IC has been used in humans to induce type I 
IFN in cancer patients and had a good safety record (Robinson 
make type I IFN via poly IC, its adjuvant effect was reduced 
by >80% (Fig. 8). These results indicate that a systemic innate 
response, and not only a local response by antigen-capturing 
DCs, accounts for the adjuvant role of poly IC.
DISCUSSION
Poly IC as a clinically feasible adjuvant for protein- 
based vaccines
Vaccines, particularly those that elicit protective T cell immunity, 
are comprised of antigens and adjuvants, with the latter influenc-
ing the quantity and quality of the specific immune response. 
Vaccine science can be extended by understanding the mecha-
nism of adjuvant action, particularly in the setting of the intact 
Figure 6.  Production of IFN- by multiple cell types. (A) Splenocytes from WT mice were depleted with Ter119, CD3, and CD19 biotinylated 
antibodies using streptavidin magnetic beads before cell sorting. For monocytes, macrophages, and granulocytes, splenocytes were additionally depleted 
of DX5+ cells. cDCs (CD3DX5CD11chiCD8 and CD8+DEC205+), pDCs (CD3DX5CD11clowB220+), NK cells (CD3DX5+), macrophages (CD11blowF4/80+), 
monocytes (CD11bhiCD115+), and granulocytes (CD11bhiLy6G+) were sorted based on their expression of specific markers (see text). Numbers 1–6 indicate 
the different cell types sorted. (B) Highly purified cells were plated at 3 × 105 cells/well in a round-bottomed 96-well plate and incubated with 50 µg/ml 
poly IC or medium alone. Splenic stromal cells, obtained as described in the Materials and methods, were plated at 5 × 104 cells/well in a 48-well plate. 
Supernatants were collected after 12 h and production of Type I IFN was detected by ELISA. (C) As in B, DEC+ DCs, monocytes, stromal cells from WT, 
TLR3, and mda5-deficient mice were stimulated in vitro with 50 µg/ml poly IC or medium alone. (D) WT and mda5/ mice were lethally irradiated and 
injected with bone marrow cells from WT or mda5/ mice. After 6 wk, chimeras were injected with 50 µg poly IC. Serum was collected 6 h later and ana-
lyzed by Type I IFN ELISA kit. Error bars show the means ± SD from at least two experiments. ND, not detectable.JEM VOL. 206, July 6, 2009 
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vivo after administration of poly IC emanates from non-
hematopoietic radioresistant cells. We proceeded to analyze the 
contribution of the type I IFN response to adjuvant action.
Type I IFN but not type II or IL-12 p40 mediates  
the adjuvant action of poly IC
A recognized feature of adjuvants is the induction of inflamma-
tory cytokines through PRR (Kool et al., 2008; Li et al., 2008). 
We find that one type of cytokine, type I IFN, dominated the 
adjuvant role of poly IC during CD4+ Th1 immunity in vivo. 
et al., 1976). These studies were directed purely to the innate 
IFN response, rather than adjuvanting adaptive Th1 immu-
nity. Also, Stahl-Hennig et al. (2009) have shown that poly 
IC is a more potent adjuvant than other agonists for responses 
to protein antigens in rhesus macaques. We find that poly IC 
is  superior  to  several  other  candidate  adjuvants  and  have 
identified important mechanistic aspects. For example, al-
though both monocytes and DEC+ DCs are able to make 
type I IFN in response to poly IC, we found in bone marrow 
chimera experiments that the main source of type I IFN in 
Figure 7.  The adjuvant role of poly IC is dependent on type I IFNs and independent of IL-12 p40. (A) CxB6 F1 mice were injected i.p. with 5 µg 
-DEC-p24 or 10 µg gag-p41 and 50 µg poly IC together with anti-IFNAR1 or isotype control. Mice were boosted with the same conditions at 4 wk. 1 wk 
later, HIV gag-specific CD3+ CD4+ splenic T cells were analyzed for IFN-. (B–E) As in A, the percentage of CD3+ CD4+ T cells producing IFN- was mea-
sured in WT, IFNAR/, STAT-1/, IFN-R/, and IL-12 p40/ immunized mice, respectively. Means ± SD are shown of two independent experiments 
with a total of six mice. ***, P = 0.001.1598 ROLE OF TYPE I INTERFERON IN POLY IC ADJUVANTICITY | Longhi et al.
rather than bacteria and parasites, and does not require the 
presence of IL-12 for the induction of Th1 immunity.
Type I IFN activates NK cells to produce type II IFN in vivo, 
but the latter is not required for the adjuvant action  
of poly IC
Another major pathway to Th1 immunity involves NK cells. 
NK cells are rapidly recruited to lymph nodes and splenic white 
pulp upon stimulation with mature DCs or some adjuvants like 
R-848 and poly IC, providing an early source of IFN-  
required for Th1 polarization (Martin-Fontecha et al., 2004; 
Grégoire et al., 2008). In addition, the production of pro-
inflammatory cytokines by NK cells has been associated with the 
adjuvant effect of poly IC (Salem et al., 2006). Specifically, 
engagement of NKp30 by DC induces secretion of proinflam-
matory cytokines by NK cells, e.g., TNF-, which has been 
identified as an active inducer of DC maturation (Vitale et al., 
2005). NK cells may have additional roles in inducing DC matu-
ration, e.g., by direct cell contact and by selective killing of 
mature DCs that do not express optimal levels of MHC class I 
molecules (Ferlazzo et al., 2001). Several inflammatory cytokines 
stimulate NK cell proliferation and IFN- production. For ex-
ample, IL-12 synergizes with IL-18 or IL-15 to induce IFN-, 
whereas IFN- promotes NK proliferation and cytotoxicity 
(Okamura et al., 1995; Yoshimoto et al., 1998; Fehniger et al., 
1999; Kim et al., 2000; Chakir et al., 2001). In this paper, we 
have found that poly IC induces strong IFN- production by 
NK cells and that this is fully dependent on the production of 
type I IFN in vivo by direct NK stimulation or though synergism 
with other cytokines, i.e., IL-18 (Matikainen et al., 2001). Yet 
IFN- was not needed for CD4+ Th1 responses or DC matura-
tion, which was normal in mice genetically lacking IFN- re-
ceptor. It remains possible that NK cells serve other roles in the 
adjuvant effects of poly IC, i.e., independent of type II IFN.
Although type I IFN has been proposed to have a role during 
clonal expansion and survival of CD8+ T cells, its role in CD4+ 
Th1 development was unclear (see Introduction). However, 
prior experiments were done in vitro with recombinant cyto-
kines and using CD3 antibody stimulation or transgenic mod-
els, making it difficult to extrapolate in vivo. We did consider 
the possibility that type I IFN could act indirectly by promot-
ing secretion of other Th1-enhancing cytokines, IL-12 and 
IFN-. IL-12 plays a crucial role in Th1 priming (Trinchieri, 
1994), whereas IFN- increases responsiveness to IL-12 and, in 
addition, activates the Th1-specific transcription factor T-bet 
(Lighvani et al., 2001; Afkarian et al., 2002). Nevertheless, our 
findings in vivo show that deletion of IL-12 p40 or IFN- re-
ceptor genes did not abrogate the CD4+ T cell response to a 
protein plus poly IC vaccine, which predominantly depends on 
type I IFN to be an adjuvant.
The relevance of IL-12 in vivo seems to depend on the 
nature of the infecting or immunizing agent. IL-12 is a major 
cofactor for Th1 differentiation during infection with several 
bacteria and parasites (Gazzinelli et al., 1994; Cooper et al., 
1997) as well as soluble antigens together with adjuvant, e.g., 
MPLA, Quil A, and CpG (Magram et al., 1996; Smith et al., 
1999; Puggioni et al., 2005; Iborra et al., 2008). Yet for some 
virus infections, e.g., lymphocytic choriomeningitis virus and 
mouse hepatitis virus, the lack of IL-12 has little or no effect 
on  the  induction  of  Th1  immunity  (Schijns  et  al.,  1998;   
Oxenius et al., 1999). One criterion for the selection of a 
suitable Th1 adjuvant has been the production of IL-12 by 
DCs in vitro, in particular, when searching for synergistic ef-
fects of multiple TLR ligands (Napolitani et al., 2005). In 
contrast, we could not detect systemic production of IL-12 
p70 after administration of poly IC, whereas poly IC was su-
perior at inducing systemic type I IFNs. Our findings indi-
cate  that  poly  IC  mimics  infections  with  certain  viruses, 
Figure 8.  Both hematopoietic and nonhematopoietic cells contribute to the adjuvant effect of poly IC. (A) Gag p24-specific CD4+ T cell re-
sponses were evaluated in bone marrow chimeras. WT and double TLR3.mda5/ mice were lethally irradiated and injected with bone marrow cells from 
WT or deficient mice. After 6 wk, chimeras were primed and boosted 4 wk apart with 5 µg -DEC-p24 and 50 µg poly IC. After 1 wk, HIV gag-specific 
CD3+CD4+ splenic T cells were analyzed for IFN- secretion. Means ± SD from two experiments are shown; n = 6. (B) Chimerism was assessed by expres-
sion of mda5 on CD11c+ splenic cells. ***, P = 0.001.JEM VOL. 206, July 6, 2009 
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that adjuvants become more effective when they induce a 
systemic inflammatory response during the time that the an-
tigen is captured and presented by DCs. In experiments that 
were not published, we found that the Th1 response was re-
duced if the administration of poly IC either preceded or fol-
lowed the administration of protein antigen by 6 h. The 
systemic production of type I IFNs enhances two key innate 
responses in vivo: the maturation of DCs and the activation 
of NK cells, as well as key adaptive lymphocytes mediating 
delayed type hypersensitivity (Gallucci et al., 1999), humoral 
immunity (Le Bon et al., 2001), and CD8 T cell memory 
(Ferrantini et al., 1994). The further development of adju-
vants may well need to consider the contributions of both 
hematopoietic and nonhematopoietic cells, which make in-
nate cytokines that work directly on DCs so that they can act 
as initiators of antigen-specific adaptive immunity.
Materials and Methods
Mice.  C57BL/6,  BALB/c,  and  CxB6  F1  were  obtained  from  Harlan,   
129/SvJ, IFNR/, and IL-12 p40/ were obtained from The Jackson 
Laboratory, STAT1/ were provided by D. Levy (New York University, 
NY, NY), IFNAR/ were provided by K. Murali-Krishna (University of 
Washington, Seattle, WA), and TLR3/ were provided by S. Akira (Osaka 
University, Osaka, Japan). Mice were maintained under specific pathogen-free 
conditions and used at 7–8 wk of age according to Institutional Animal Care 
and Use guidelines. Animal protocols were approved by the Institutional 
Animal Care and Use Committee (IACUC).
In vivo cytokine secretion. Mice were injected i.p. with 50 µg poly IC 
(InvivoGen), 50 µg Pam3cys (InvivoGen), 0.5 µg Malp2 (Enzo Biochem, 
Inc.), 10 µg LPS (E. Coli; Sigma-Aldrich), 50 µg poly ICLC (Oncovir, Inc.), 
50 µg CpG ODN1826 (InvivoGen), or R-848 cream (2% topically applied 
to 5 cm2 of back skin; Celldex Therapeutics, Inc.), and serum was col-
lected at the indicated times. Production of TNF-, IL-12p40, IL-12p70, 
IL-6, IFN- (eBioscience), and IFN- and IFN- (R&D Systems) was   
determined by ELISA according to the manufacturer’s instructions.
Cell sorting and stromal cell isolation. Spleens were cut in small pieces 
and incubated at 37°C for 30 min in Hank’s medium supplemented with   
400 U/ml collagenase d (Roche). EDTA (5 mM in final concentration) was 
added for the last 5 min. Cells were stained with biotinylated anti-CD3, anti-
CD19, and anti-Ter119 mAbs (BD) for 20 min, washed, incubated with 
Streptavidin-coated magnetic beads, and passed through LD columns (Miltenyi 
Biotec). The negative fraction was collected and stained with Live/Dead 
Fixable Aqua viability dye (Invitrogen), FITC–anti-DX5, PE–anti-CD11c, 
PercPCy5.5-B220,  Pacific  Blue–anti-CD3,  Alexa  Fluor  750–anti-CD8 
(eBioscience), and Alexa Fluor 647–DEC-205 (produced in house). Alterna-
tively, cells were stained with Fixable Aqua viability dye, FITC–anti-Ly6G, 
PE–anti-CD115, PerCP–anti-F4/80, PE-Cy7–anti-CD11c, and Alexa Fluor 
750–CD11b (eBioscience). Different populations were isolated by sorting on 
a FACSAria with DiVa configuration (BD). Splenic stromal cells were ob-
tained as previously described (Cheng et al., 2007). In brief, spleens were cut 
into small fragments, placed in a 48MW plate, and cultured in RPMI 1640 
medium supplemented with 20% FCS and 1% MEM nonessential amino   
acids. After 1 mo, cells were further purified by CD45 negative selection.
ELISA for antibody response. To detect gag-specific antibody, high-
binding ELISA plates (BD) were coated with 1 µg/ml of gag protein over-
night at 4°C, washed with PBS/0.1% Tween 20, and blocked with PBS/5% 
BSA for 1 h at 37°C. Serial dilutions of serum were added to the plates and 
incubated for another 1 h at 37°C. Plates were washed and incubated 1 h at 
37°C with secondary HRP goat anti–mouse IgG antibody (Jackson Immuno-
research  Laboratories).  TMB  (3,3,5,5-tetramethylbenzidine)  substrate   
Innate type I IFNs in vivo induce DCs to stimulate  
adaptive immunity
The major challenge to understanding adjuvant function in 
vivo is, by definition, to understand the induction of adaptive 
immunity and how an early innate response to an adjuvant 
leads to adaptive immunity. Immunity induced by vaccination 
requires two broad functions at the level of DCs but needs to 
be studied in vivo. One is antigen presentation, which we en-
hanced by targeting the HIV gag protein to the DEC-205   
antigen uptake receptor on a subset of DCs. Nevertheless,   
our mechanistic findings were similar when we administered 
higher doses of the antigen as an isolated gag p41 protein. The 
second function is that antigen-capturing DCs need to mature 
in vivo to induce immunity, as shown initially with another 
adjuvant, -galactosyl ceramide (Fujii et al., 2003). Addition-
ally, maturation is required to avoid T cell tolerance upon tar-
geting of antigens to DCs (Hawiger et al., 2001; Bonifaz et al., 
2002; Kretschmer et al., 2006; Yamazaki et al., 2008). Our ex-
periments show that type I IFN is important for DC matura-
tion after poly IC. Poly IC and type I IFNs were each known 
to induce DC maturation, but their interdependence had not 
previously been tested in vivo. Likewise, Le Bon et al. (2001) 
found that type I IFNs could act on ex vivo–derived DCs, 
which then stimulates antibody immunity. We noted that poly 
IC not only up-regulates DC costimulatory molecules but al-
lows DCs to become better inducers of MLR. The latter assay 
remains valuable to document that DCs have matured in the 
critical functional sense and not only by altering their cell sur-
face phenotype. Both changes in DCs, i.e., up-regulation of 
CD86 and increased MLR stimulation, were abrogated by 
blockade of type I IFN receptors. Although ligation of PRRs 
has previously been associated with some features of DC matu-
ration, we showed that this is not sufficient by itself and, addi-
tionally,  the  development  of  immunostimulatory  function 
requires direct IFNAR signaling of the DCs.
Both bone marrow–derived and nonhematopoietic cells 
need to respond to poly IC
Elegant studies have shown that antigen-presenting cells must 
themselves respond to TLR agonists to induce strong clonal 
expansion of antigen-specific TCR transgenic T cells (Spörri 
and Reis e Sousa, 2005; Nolte et al., 2007), but the response 
of naive mice and the contribution of radioresistant cells was 
not fully evaluated. Unexpectedly, we found that the adju-
vant role of poly IC for a primary CD4+ T cell response was 
severely reduced when either bone marrow–derived or ra-
dioresistant cells lacked the mda-5 and TLR3 PRRs. Radio-
resistant cells could include endothelial, epithelial, and stromal 
cells. The Langerhans type of DC is also radioresistant (Merad 
et al., 2002), but we found that depletion of these cells did 
not alter the levels of type I IFN detected in the serum. In 
contrast, we showed that stromal cells in vitro produced type 
I IFN as effectively as DCs upon poly IC stimulation, and in 
ongoing experiments, we find that poly IC markedly in-
creases type I IFN mRNA in liver and lung cells suspensions 
that are depleted of CD11c+ cells. These findings indicate 1600 ROLE OF TYPE I INTERFERON IN POLY IC ADJUVANTICITY | Longhi et al.
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